PuSH - Publication Server of Helmholtz Zentrum München: Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Morra, A.* ; Schreurs, M.A.C.* ; Andrulis, I.L.* ; Anton-Culver, H.* ; Augustinsson, A.* ; Beckmann, M.W.* ; Behrens, S.* ; Bojesen, S.E.* ; Bolla, M.K.* ; Brauch, H.* ; Broeks, A.* ; Buys, S.S.* ; Camp, N.J.* ; Castelao, J.E.* ; Cessna, M.H.* ; Chang-Claude, J.* ; Chung, W.K.* ; Colonna, S.V.* ; Couch, F.J.* ; Cox, A.* ; Cross, S.S.* ; Czene, K.* ; Daly, M.B.* ; Dennis, J.* ; Devilee, P.* ; Dörk, T.* ; Dunning, A.M.* ; Dwek, M.* ; Easton, D.F.* ; Eccles, D.M.* ; Eriksson, M.* ; Evans, D.G.* ; Fasching, P.A.* ; Fehm, T.N.* ; Figueroa, J.D.* ; Flyger, H.* ; Gabrielson, M.* ; Gago-Dominguez, M.* ; Garcia-Closas, M.* ; García-Sáenz, J.A.* ; Genkinger, J.* ; Grassmann, F.* ; Gündert, M. ; Hahnen, E.* ; Haiman, C.A.* ; Hamann, U.* ; Harrington, P.A.* ; Hartikainen, J.M.* ; Hoppe, R.* ; Hopper, J.L.* ; Houlston, R.S.* ; Howell, A.* ; Jakubowska, A.* ; Janni, W.* ; Jernström, H.* ; John, E.M.* ; Johnson, N.* ; Jones, M.E.* ; Kristensen, V.N.* ; Kurian, A.W.* ; Lambrechts, D.* ; Le Marchand, L.* ; Lindblom, A.* ; Lubinski, J.* ; Lux, M.P.* ; Mannermaa, A.* ; Mavroudis, D.* ; Mulligan, A.M.* ; Muranen, T.A.* ; Nevanlinna, H.* ; Nevelsteen, I.* ; Neven, P.* ; Newman, W.G.* ; Obi, N.* ; Offit, K.* ; Olshan, A.F.* ; Park-Simon, T.W.* ; Patel, A.V.* ; Peterlongo, P.* ; Phillips, K.A.* ; Plaseska-Karanfilska, D.* ; Polley, E.C.* ; Presneau, N.* ; Pylkäs, K.* ; Rack, B.* ; Radice, P.* ; Rashid, M.U.* ; Rhenius, V.* ; Robson, M.* ; Romero, A.* ; Saloustros, E.* ; Sawyer, E.J.* ; Schmutzler, R.K.* ; Schuetze, S.* ; Scott, C.* ; Shah, M.* ; Smichkoska, S.* ; Southey, M.C.* ; Tapper, W.J.* ; Teras, L.R.* ; Tollenaar, R.A.E.M.* ; Tomczyk, K.* ; Tomlinson, I.* ; Troester, M.A.* ; Vachon, C.M.* ; van Veen, E.M.* ; Wang, Q.* ; Wendt, C.* ; Wildiers, H.* ; Winqvist, R.* ; Ziogas, A.* ; Hall, P.* ; Pharoah, P.D.P.* ; Adank, M.A.* ; Hollestelle, A.* ; Schmidt, M.K.* ; Hooning, M.J.*

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

Cancer Med. 12, 16142-16162 (2023)

Postprint

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

BACKGROUND: Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. AIM: To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. METHODS: Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. RESULTS: There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55-0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09-1.56)]. CONCLUSION: Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.

Impact Factor

Scopus SNIP

Altmetric

4.000

0.000